| Kythera Biopharmaceuticals Announces Second Phase II Clinical Trial With Adipolytic Agent For Reduction Of Submental Fat Kythera Biopharmaceuticals, Inc. ("Kythera") announced the initiation of a second Phase II clinical trial evaluating its proprietary product, ATX-101, for the reduction of unwanted submental (under chin) fat. This clinical trial is the second in a series of Phase II studies of ATX-101 in aesthetic applications and is aimed at assessing the safety and effectiveness of ATX-101 as a "liposculpting" agent. medicalnewstoday.com |
Statement From British Association Of Cosmetic Doctors Warning Against "Discount Injectables" The British Association of Cosmetic Doctors has warned that people searching for lower priced cosmetic treatments may lead to a surge in problems associated with "discount injectables" bought from unreliable suppliers and administered by poorly trained practitioners. medicalnewstoday.com |
New Type Of Botulinum Toxin Appears To Be Well Tolerated And May Help Reduce Forehead Wrinkles Injections with a new type of botulinum toxin appears to be well tolerated and may help to improve the appearance of moderate to severe forehead lines with no evidence of diminishing treatment response over 13 months, according to a report in the March/April issue of Archives of Facial Plastic Surgery, one of the JAMA/Archives journals. medicalnewstoday.com |
BJOG Release: Study Raises Concerns About Cosmetic Labial Surgery New research to be published in BJOG: An International Journal of Obstetrics and Gynaecology reviews the available literature on cosmetic labial surgery and underlines the striking lack of evidence on the safety and long-term consequences of such procedures... mnt.to |
Breakthrough For Babies Born With Severe Cleft Palates After Experiments At ISIS Scientists working on a treatment for babies born with cleft palates have made a promising breakthrough and the first clinical trials are planned for early next year... mnt.to |